ATE147634T1 - Produkte zur behandlung des endotoxin -schocks bei einem säugetier - Google Patents

Produkte zur behandlung des endotoxin -schocks bei einem säugetier

Info

Publication number
ATE147634T1
ATE147634T1 AT89121661T AT89121661T ATE147634T1 AT E147634 T1 ATE147634 T1 AT E147634T1 AT 89121661 T AT89121661 T AT 89121661T AT 89121661 T AT89121661 T AT 89121661T AT E147634 T1 ATE147634 T1 AT E147634T1
Authority
AT
Austria
Prior art keywords
mammal
products
endotoxin shock
effective amount
therapeutically effective
Prior art date
Application number
AT89121661T
Other languages
English (en)
Inventor
Allan Wissner
Suresh S Kerwar
Constance Kohler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE147634T1 publication Critical patent/ATE147634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Percussive Tools And Related Accessories (AREA)
  • Disintegrating Or Milling (AREA)
  • Thermistors And Varistors (AREA)
  • Measurement Of Force In General (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT89121661T 1988-12-19 1989-11-23 Produkte zur behandlung des endotoxin -schocks bei einem säugetier ATE147634T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28620188A 1988-12-19 1988-12-19

Publications (1)

Publication Number Publication Date
ATE147634T1 true ATE147634T1 (de) 1997-02-15

Family

ID=23097534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89121661T ATE147634T1 (de) 1988-12-19 1989-11-23 Produkte zur behandlung des endotoxin -schocks bei einem säugetier

Country Status (18)

Country Link
US (1) US5124147A (de)
EP (1) EP0374510B1 (de)
JP (1) JP2931344B2 (de)
KR (1) KR0148680B1 (de)
AT (1) ATE147634T1 (de)
AU (1) AU624457B2 (de)
CA (1) CA2005670A1 (de)
DE (1) DE68927671T2 (de)
DK (1) DK641889A (de)
ES (1) ES2096553T3 (de)
FI (1) FI896046A7 (de)
GR (1) GR3022969T3 (de)
IL (1) IL92471A (de)
NZ (1) NZ231725A (de)
PH (1) PH31376A (de)
PT (1) PT92596B (de)
SG (1) SG43205A1 (de)
ZA (1) ZA899685B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231091A (en) * 1988-12-19 1993-07-27 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
DE69129460T2 (de) * 1990-08-31 1998-10-15 Boehringer Ingelheim Pharma Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
JPH10504441A (ja) 1994-03-07 1998-05-06 カイロン コーポレイション Ｔｎｆ形成阻害のための組成物およびその使用
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
KR100528604B1 (ko) * 1995-01-23 2006-03-16 제노테크 인코포레이티드 골용해와전이를개선하기위한조성물
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP1851245B1 (de) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antikörper gegen interleukin-1-beta
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
EP2738179A1 (de) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antikörperreinigung
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2445932B1 (de) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soriciden-abgeleitete peptide und verfahren zum nachweisen von trpv-6-krebsarten und medikamentenverabreichung
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters

Also Published As

Publication number Publication date
JP2931344B2 (ja) 1999-08-09
NZ231725A (en) 1992-12-23
CA2005670A1 (en) 1990-06-19
SG43205A1 (en) 1997-10-17
JPH02212435A (ja) 1990-08-23
DE68927671D1 (de) 1997-02-27
DK641889A (da) 1990-06-20
DK641889D0 (da) 1989-12-18
EP0374510B1 (de) 1997-01-15
IL92471A0 (en) 1990-08-31
PT92596B (pt) 1996-06-28
AU624457B2 (en) 1992-06-11
US5124147A (en) 1992-06-23
KR900009097A (ko) 1990-07-02
EP0374510A1 (de) 1990-06-27
FI896046A7 (fi) 1990-06-20
DE68927671T2 (de) 1997-05-07
GR3022969T3 (en) 1997-06-30
FI896046A0 (fi) 1989-12-18
ES2096553T3 (es) 1997-03-16
PH31376A (en) 1998-10-29
IL92471A (en) 1995-06-29
PT92596A (pt) 1990-06-29
KR0148680B1 (ko) 1998-08-17
AU4688589A (en) 1990-06-21
ZA899685B (en) 1990-09-26

Similar Documents

Publication Publication Date Title
DE68927671D1 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
ATE172880T1 (de) Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
ZA929446B (en) Therapeutic method
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
EP0481970A3 (en) Monoclonal antibodies against endotoxin of gram-negative bacteria
IL93840A0 (en) Novel monoclonal antibody to novel antigen associated with human tumors
DK0492448T3 (da) Monoklonale antistoffer mod human tumor-nekrotiserende faktor alfa
DK149990D0 (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
ATE101876T1 (de) Verfahren zur verringerung der heterogenitaet von monoklonalen antikoerpern.
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des "nicht-kleine-zellen"-typs.
ATE93144T1 (de) Methode zur verminderung der immunglobulin-ereaktion.
IT1231727B (it) Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
ATE98872T1 (de) Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
DE69006221D1 (de) Verfahren zur behandlung von septischem schock.
GB2254326B (en) Monoclonal antibodies produced by in vitro immunization of lymphocytes
FI911311A7 (fi) Gramnegatiivisten bakteerien endotoksiinin vaikutuksen ehkäiseviä mono klonaalisia vasta-aineita
DK717888A (da) Monoklonale antistoffer
DK592086A (da) Humant conglutinin
IT1163911B (it) Resina per lenti di elevata rifrattivita' e lenti prodotte con la resina stessa
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
FI895829A7 (fi) Ihmisen monoklonaaliset vasta-aineet rabiesvirusta vastaan
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59
CS511090A3 (en) Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2
FI900960A7 (fi) Menetelmä lentotuhkan betoniteknisten ominaisuuksien parantamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee